An equation for estimating low-density lipoprotein-triglyceride content and its use for cardiovascular disease risk stratification.

Front Cardiovasc Med

Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States.

Published: October 2024

Background: The triglyceride (TG) content of low-density lipoprotein (LDL-TG) has been shown to be more predictive of atherosclerotic cardiovascular disease (ASCVD) events than the cholesterol content of LDL (LDL-C). The goal of our study was to develop an equation for estimating LDL-TG (LDL-TG) based on the standard lipid panel and to compare it to estimated LDL-C as an ASCVD risk biomarker.

Methods: Using least-square regression analysis, the following LDL-TG equation was developed: . LDL-TG was measured by the -quantification (BQ) reference method ( = 40,202). LDL-C was calculated by the Sampson-NIH equation. The association of LDL-C and LDL-TG with ASCVD risk markers was performed in the National Heart and Nutrition Examination Survey (NHANES) ( = 37,053) and with ASCVD events in a primary prevention cohort from the UK Biobank (UKB) ( = 429,367) and the Atherosclerosis Risk in Communities (ARIC) study ( = 14,632).

Results: LDL-TG showed better ASCVD risk stratification of UKB participants than LDL-C (Wilcoxon Chi-Square: 2,099.6 vs. 418.7, respectively). Receiving-operating characteristics analysis revealed that LDL-TG had a stronger association with ASCVD events than LDL-C (AUC: 0.596 vs. 0.542, respectively) and other conventional lipid markers. Similar findings were found in ARIC. Discordance analysis in UKB showed that the group with low LDL-C/high LDL-TG had a similar risk as the high LDL-C/high LDL-TG group. Furthermore, these same two groups with the highest LDL-TG levels and the highest ASCVD event rate also had higher mean levels of systolic blood pressure, Body Mass Index, hemoglobin A1C, and C-reactive protein than the two lower LDL-TG groups. Using LDL-TG > 44.6 mg/dl (80th percentile) as a cut-point leads to a hazard ratio of 1.32 (95% CI, 1.29-1.36) for ASCVD events, which remained significant after adjustment for LDL-C and apoB. Furthemore, using LDL-TG as a risk-enhancer test leads to reclassification of 50% more high-risk individuals than current lipid-enhancer test rules.

Conclusions: Like LDL-C, LDL-TG can also be calculated from the results of the standard lipid panel. Compared to estimated LDL-C, LDL-TG was a better risk marker for primary prevention and hence could improve initial ASCVD risk stratification.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543484PMC
http://dx.doi.org/10.3389/fcvm.2024.1452869DOI Listing

Publication Analysis

Top Keywords

ascvd events
16
ascvd risk
16
ldl-tg
15
risk stratification
12
ldl-c ldl-tg
12
ascvd
9
ldl-c
9
equation estimating
8
cardiovascular disease
8
risk
8

Similar Publications

Background: There is significant heterogeneity in cardiovascular disease (CVD) risk among patients with diabetes mellitus (DM).

Objectives: The purpose of this study was to develop risk scores for total CVD and its components from a contemporary pooled, observational cohort of U.S.

View Article and Find Full Text PDF

Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes.

BMC Med

January 2025

Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China.

Background: Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE.

Methods: In total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry.

View Article and Find Full Text PDF

Atherosclerotic cardiovascular disease (ASCVD) is a leading global cause of mortality, and recent research has underscored the critical role of lipoproteins in modulating cardiovascular (CV) risk. Elevated low-density lipoprotein cholesterol (LDL-C) levels have been linked to increased CV events, and while numerous trials have confirmed the efficacy of lipid-lowering therapies (LLT), significant gaps remain between recommended LDL-C targets and real-world clinical practice. This review addresses care gaps in LLT, emphasizing the necessity for innovative approaches that extend beyond LDL-C management.

View Article and Find Full Text PDF

Differences in Statin Eligibility with the Use of Predicting Risk of Cardiovascular Disease EVENTs Versus Pooled Cohort Equations in the UK Biobank.

Am J Cardiol

January 2025

Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL 35233; Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, AL 35233. Electronic address:

The Pooled-Cohort Equations (PCEs), developed by the American Heart Association (AHA) and American College of Cardiology (ACC), have been widely used since 2013 to estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk and guide statin therapy. Recently, the AHA introduced the Predicting Risk of CVD EVENTs (PREVENT) equations to improve ASCVD risk estimation. However, the effect of using PREVENT instead of PCEs on risk classification and statin eligibility remains unclear.

View Article and Find Full Text PDF

The first step to reducing the growing burden of cardiovascular disease (CVD) is to find modifiable risk factors with the highest burden in each population. Urban and rural citizens may have different priorities in this regard. This study aimed to compare the 10-year incidence probability of CVD events and its associated risk factors between rural and urban areas in Iran.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!